Purple Biotech Announces AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody Platform Purple Biotech (NASDAQ: PPBT) announced a collaboration with Converge Bio on March 25, 2026 to apply proprietary generative AI to accelerate and optimize its next-generation tri-specific antibody platform for oncology. The partnership targets faster discovery, improved developability, and expanded capability against solid-tumor targets.The collaboration will integrate Converge Bio's AI-driven molecule design with Purple Biotech's CAPTN-3 conditional activation technology to generate optimized T cell engagers and additional high-quality candidates.

#PPBT Purple Biotech Announces AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody Platform

www.stocktitan.net/news/PPBT/purple-biotech...

Purple Biotech Announces CEO Transition Purple Biotech (NASDAQ/TASE: PPBT) announced that Gil Efron will step down as CEO effective August 2026 for health reasons and will transition to lead corporate development while remaining on the Board.The Board has begun a formal CEO search; the company highlighted continued focus on the CAPTN-3 tri-specific antibody platform and an orderly leadership transition.

#PPBT Purple Biotech Announces CEO Transition

www.stocktitan.net/news/PPBT/purple-biotech...

Purple Biotech Reports Fourth Quarter and Full Year 2025 Financial Results Purple Biotech (NASDAQ:PPBT) reported Q4 and full-year 2025 results highlighting advancement of its CAPTN-3 tri-specific antibody program. Lead molecules IM1240 and IM1305 showed positive preclinical efficacy, expanded toxicology window and commercially viable manufacturing yield. Key figures: cash $9.5M (Dec 31, 2025) with runway into 2027, $20.5M impairment for CM24/NT219, and $26.4M net loss for 2025.

#PPBT Purple Biotech Reports Fourth Quarter and Full Year 2025 Financial Results

www.stocktitan.net/news/PPBT/purple-biotech...

Trade Alerts, Tuesday January 13, 2026 – Crystal Equity Research

Small-cap stocks with improving money flow, Tue Jan 13th - #XBIT #WLDN #SRTS #PPBT #MITK #KROS #ICHR #FBRX #ELE #DOGZ #CMTL #BBSI #ADAM #TDF #PSBD #MVO #YI #LEG #EVC #BW - More: crystalequityresearch.com/trade-alerts... - #smallcap

Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240 IM1240 demonstrated improved safety in a toxicology study at doses up to 300-fold higher than a non-capped comparator IM1240's pharmacokinetic profile showed increased systemic exposure and a prolonged circulating half-life enabled by its human serum albumin moiety and capping design IM1240 on

#PPBT Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240

www.stocktitan.net/news/PPBT/purple-biotech...

🔞Happy Thanksgiving 🦃🍁 to all. I stuffed my turkey🍑 really well felt so great 😃 I was hard a rock. I was gooning out while I was #fisting his #Ass with my barehanded filling his insides🤤👊.
#ppbt #gooning #popperbate #edgingmypenis #penis #Rawfuck #kinky #bator #fisting

Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update Purple Biotech (NASDAQ: PPBT) reported Q3 2025 results and a business update on Nov 14, 2025. Key financials: $10.5M cash and short-term deposits as of Sept 30, 2025, with an expected cash runway into the first half of 2027. Q3 operating loss was $1.4M and adjusted operating loss $1.3M. R&D expenses declined to $0.6M (56% decrease YoY) largely from reduced CM24 Phase 2 costs.Clinical and pipeline highlights: IM1240 achieved a commercially viable manufacturing yield and is being advanced toward an IND and Phase 1 initiation in 2026. IM1305 was nominated as a second CAPTN-3 tri-specific candidate targeting TROP2. NT219 Phase 2 and CM24 biomarker-driven plans continue.

#PPBT Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/PPBT/purple-biotech...

🚀 Exciting times for #PPBT! Trading at $0.8666, it's breaking key moving averages with bullish momentum. MACD is positive, RSI healthy, and volume spikes hint at more gains. Consider a long position with targets at $0.90 & $0.95. Stay sharp, watch the market! 📈 #FeetrAI

🚀 Exciting times for #PPBT! With positive trial results and an upcoming FDA decision, Purple Biotech is on the move. Recent surge from $0.57 to $1.41 shows strong interest. Consider a LONG at $0.86, targeting $0.95 & $1.05. Stay alert for news! 📈 #Biotech #Stocks #FeetrAI

🚀 Exciting times for #PPBT! With an 82% surge driven by clinical trial buzz, Purple Biotech is on a bullish run. 📈 Technicals show upward momentum with MACD & RSI supporting gains. Consider a long position at $0.76, targeting $0.85-$0.90. Stay sharp, volatility ahead! #Biotech #Stocks

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! Weekly Top Unu

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

Weekly Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #PPBT 170% OTM
2. #CRCL 91% OTM
3. #CMBM 74% OTM
4. #KYTX 59% OTM
5. #NKLR 58% OTM

#OptionFlow #OptionsTrading #Trading

🚀 Exciting times for #PPBT! With strong bullish momentum from promising phase 3 cancer trial results and potential big pharma partnerships, the stock is trending above key moving averages. 📈 Consider a long position at $0.90 with targets at $1.00 & $1.10. #BiotechBoom

🚀 Exciting times for #PPBT! Bullish momentum is surging after successful Phase 3 cancer trial results. 📈 With strong upward pressure and positive MACD, consider a long position at $0.98. Targets: $1.10 & $1.20. Stop loss: $0.90. Stay sharp, volatility ahead! #BiotechBoom

🚀 Exciting times for #PPBT! With strong bullish momentum, it's trading at $0.869, well above key moving averages. RSI is high, hinting at overbought conditions, but the MACD supports further gains. Consider a LONG position targeting $0.95 & $1.05. Stay cautious! 📈 #Stocks #FeetrAI

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#PPBT, #RKLB, #WOLF, #CLS, #FLNC

#OptionFlow #OptionsTrading #Trading

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! PM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #PPBT 170% OTM
2. #BYND 114% OTM
3. #CRCL 87% OTM
4. #CORZ 47% OTM
5. #RDDT 36% OTM

#OptionFlow #OptionsTrading #Trading

🚀 Exciting times for #PPBT! Trading volume is soaring, and the stock's price is above key moving averages. With positive momentum from clinical trials, a long position could target $1.10 & $1.25. But watch out for overbought signals and market volatility! 📈 #FeetrAI

🚀 Exciting times for #PPBT! Trading volume is soaring, but with a 6-day RSI at 91.19, it's in overbought territory. Consider a short position at $0.94, targeting $0.85 & $0.80, with a stop loss at $1.05. Stay alert for news that could shake things up! 📈 #FeetrAI

📢 Stocks Trending NOW: #NVDA #BA #FI #NOK #VZ #CAT #CMBM #BE #PPBT #CVS

🚀 Exciting times for #PPBT! Trading volume is soaring, signaling big moves ahead. With bullish momentum and positive clinical trial buzz, this biotech gem is on the rise. Consider a long position at $1.05, targeting $1.20 & $1.30. 📈 But remember, biotech = risk! #FeetrAI

Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform Purple Biotech (NASDAQ: PPBT) announced a manufacturing milestone for IM1240, a CAPTN-3 tri-specific antibody targeting 5T4, CD3 and NKG2A. The company reports achieving a commercially viable yield and high-purity process for IM1240, validating CAPTN-3's scalability for complex tri-specific antibodies. IM1240 includes a protease-cleavable, albumin-bound cap intended to limit systemic CD3 activation and extend half-life, concentrating activity in the tumor microenvironment. The program is advancing toward first-in-human studies with an IND submission planned for 2026.

#PPBT Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform

www.stocktitan.net/news/PPBT/purple-biotech...

Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification Purple Biotech (NASDAQ/TASE: PPBT) received a Nasdaq notice on Oct 16, 2025 that its American Depositary Shares closed below the required $1.00 minimum for 30 consecutive trading days. Under Nasdaq Listing Rule 5810(c)(3)(A) the company has a 180‑day cure period until April 14, 2026 to regain compliance by achieving a closing bid ≥ $1.00 for ten consecutive business days. The notice does not affect the current Nasdaq listing or trading of ADSs, nor its Tel Aviv listing. If noncompliant by April 14, 2026, Purple Biotech may be eligible for a second 180‑day period if it meets market‑value and other listing standards, or face delisting and the option to appeal. The company said it will monitor the ADS price and may consider options such as changing the ADS-to-ordinary share ratio to regain compliance.

#PPBT Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification

www.stocktitan.net/news/PPBT/purple-biotech...

Novel Cancer Resistance Drug NT219 Advances: Purple Biotech Secures Key EU Patent for Immunotherapy Combinations Purple Biotech's NT219 patent covers combinations with immunotherapies and MEK inhibitors for resistant cancers through 2036. Phase 2 trial ongoing in head and neck cancer with pembrolizumab.

#PPBT Purple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor Resistance

www.stocktitan.net/news/PPBT/purple-biotech...

🚨 FeetrAI Alert: #PPBT is in the spotlight! Despite a recent cash boost, Purple Biotech shows bearish momentum with RSI <15. 📉 Consider a SHORT at $0.58, targeting $0.55 & $0.50. Stop loss at $0.60. Low volume = caution. Stay tuned for updates! #Biotech #Stocks

🚨 Exciting insights from FeetrAI! 🚨 #PPBT is in the spotlight with recent capital raising for oncology R&D. Despite bearish momentum and oversold RSI, volatility hints at sharp moves. Consider a SHORT at $0.57, targeting $0.55 & $0.52. Stay cautious! 📉 #StockAnalysis

🚨 FeetrAI Alert: #PPBT is in the spotlight! Despite a recent cash boost, bearish signals dominate with RSI oversold & MACD negative. Volume's low, but opportunity knocks for a SHORT at $0.61. Targets: $0.58 & $0.55. Stop loss: $0.63. Stay sharp, traders! 📉 #Stocks #Biotech

🚀 Exciting times for #PPBT! With fresh funding fueling their oncology pipeline, Purple Biotech is poised for a potential rebound. Oversold signals hint at a bounce back. Consider entering at $0.62, targeting $0.68 & $0.75. Stay alert for news! 📈 #Biotech #InvestSmart

Leading Indicators, Thursday September 4, 2025 – Crystal Equity Research

Small-cap stocks gapping down in trading, Thu Sept 4th - #ARTL #SDST #PPBT #NEON #CRMT #AEMD #DOLE #DAVA #CAL #AAMI - More: crystalequityresearch.com/leading-indi... - #smallcap

🚨 Hot Stock Alert: #PPBT is on a rollercoaster! 📉 With prices at $0.8094 and trading volume soaring, the bears are in control. RSI is oversold, MACD shows negative momentum. Consider SHORT at $0.81, target $0.75/$0.70, stop loss $0.85. Stay sharp! #FeetrAI #StockMarket